The estimated Net Worth of Joshua R Lamstein is at least $12 dollars as of 26 August 2021. Joshua Lamstein owns over 400 units of Scopus Biopharma stock worth over $12 and over the last 9 years Joshua sold SCPS stock worth over $0.
Sign up
Joshua Lamstein SCPS stock SEC Form 4 insiders trading
Joshua has made over 7 trades of the Scopus Biopharma stock since 2016, according to the Form 4 filled with the SEC. Most recently Joshua bought 400 units of SCPS stock worth $1,980 on 26 August 2021.
The largest trade Joshua's ever made was buying 1,500 units of Scopus Biopharma stock on 23 July 2021 worth over $7,065. On average, Joshua trades about 308 units every 134 days since 2016. As of 26 August 2021 Joshua still owns at least 119,997 units of Scopus Biopharma stock.
You can see the complete history of Joshua Lamstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Joshua Lamstein's mailing address?
Joshua's mailing address filed with the SEC is C/O SCOPUS BIOPHARMA INC., 420 LEXINGTON AVENUE, SUITE 300, NEW YORK, NY, 10170.
Insiders trading at Scopus Biopharma
Over the last 4 years, insiders at Scopus Biopharma have traded over $0 worth of Scopus Biopharma stock and bought 21,190 units worth $148,408 . The most active insiders traders include Ira Scott Greenspan, Joshua R Lamstein e Robert J Gibson. On average, Scopus Biopharma executives and independent directors trade stock every 12 days with the average trade being worth of $0. The most recent stock trade was executed by Ira Scott Greenspan on 27 August 2021, trading 900 units of SCPS stock currently worth $4,473.
What does Scopus Biopharma do?
Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
What does Scopus Biopharma's logo look like?
Complete history of Joshua Lamstein stock trades at PAVmed Inc e Scopus Biopharma
Scopus Biopharma executives and stock owners
Scopus Biopharma executives and other stock owners filed with the SEC include:
-
Ira Scott Greenspan,
Sr. Advisor & Director -
Dr. Morris C. Laster,
Co-Chairman & CEO -
Daniel J. Politzer C.F.A.,
CFO & COO -
Robert J. Gibson,
Vice Chairman, Sec. & Treasurer -
Alan D. Horsager Ph.D.,
Pres?of?Immuno-Oncology and Pres & CEO of Olimmune Inc. -
Dr. Alan M. Horsager Ph.D.,
Pres -
David Silberg,
Sr. Advisor -
Ashish Pradip Sanghrajka,
Pres & Director -
Robert J Gibson,
Vice Chairman -
Ira Scott Greenspan,
Executive Committee Chairman -
Joshua R Lamstein,
Chairman -
Paul Hopper,
Director